Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.

ABSTRACT:

Purpose

To determine long-term outcomes in a clinical trial evaluating the role of taxane type and schedule in operable breast cancer and evaluate the impact of obesity and black race on outcome.

Patients and methods

A total of 4,954 eligible women with stage II to III breast cancer treated with four cycles of doxorubicin plus cyclophosphamide were randomly assigned to receive paclitaxel or docetaxel every 3 weeks for four doses or weekly for 12 doses using a 2 × 2 factorial design. The primary end point was disease-free survival (DFS). Results are expressed as hazard ratios (HRs) from Cox proportional hazards models. All P values are two sided.

Results

When compared with the standard every-3-week paclitaxel arm, after a median follow-up of 12.1 years, DFS significant

SUBMITTER: Sparano JA 

PROVIDER: S-EPMC4500829 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature